IDEAYA Biosciences to Announce Phase 2/3 Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy IDYA?
Source: Newsfilter
- Clinical Trial Announcement: IDEAYA Biosciences plans to issue a joint press release with Servier on April 13, 2026, at 8:00 AM ET, to disclose topline results from the ongoing Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for HLA*A2-negative metastatic uveal melanoma patients.
- Management Participation: The conference call will feature members of IDEAYA's management alongside a distinguished key opinion leader, aiming to discuss trial results and their potential implications for the company's future, thereby enhancing investor confidence.
- Webcast Information: Investors can register for the webcast through the Events section of IDEAYA's website, and a replay will be available for 30 days post-event, ensuring that those unable to attend live can still access critical information.
- Precision Medicine Mission: IDEAYA is committed to precision oncology, focusing on the discovery, development, and commercialization of transformative therapies, integrating expertise in small-molecule drug discovery and bioinformatics to develop personalized treatment options aligned with genetic disease drivers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 31.000
Low
30.00
Averages
49.86
High
79.00
Current: 31.000
Low
30.00
Averages
49.86
High
79.00
About IDYA
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEAYA Biosciences to Announce Phase 2/3 Trial Results
- Clinical Trial Announcement: IDEAYA Biosciences plans to issue a joint press release with Servier on April 13, 2026, at 8:00 AM ET, to disclose topline results from the ongoing Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for HLA*A2-negative metastatic uveal melanoma patients.
- Management Participation: The conference call will feature members of IDEAYA's management alongside a distinguished key opinion leader, aiming to discuss trial results and their potential implications for the company's future, thereby enhancing investor confidence.
- Webcast Information: Investors can register for the webcast through the Events section of IDEAYA's website, and a replay will be available for 30 days post-event, ensuring that those unable to attend live can still access critical information.
- Precision Medicine Mission: IDEAYA is committed to precision oncology, focusing on the discovery, development, and commercialization of transformative therapies, integrating expertise in small-molecule drug discovery and bioinformatics to develop personalized treatment options aligned with genetic disease drivers.
See More
IDEAYA Biosciences to Announce Phase 2/3 Trial Results for Darovasertib
- Clinical Trial Announcement: IDEAYA Biosciences plans to issue a joint press release with Servier on April 13, 2026, at 8:00 AM ET, disclosing topline results from the ongoing Phase 2/3 registrational trial, OptimUM-02, which evaluates darovasertib in combination with crizotinib for first-line HLA*A2-negative metastatic uveal melanoma patients.
- Management Involvement: The conference call will feature members of IDEAYA's management alongside a distinguished key opinion leader, aiming to discuss trial results and their potential implications for the company's future, thereby enhancing investor confidence in the strategic direction.
- Webcast Information: Webcast registration details can be accessed via the Events section of IDEAYA's website, and a replay will be available for 30 days post-event, ensuring that investors who cannot attend live can still access critical information.
- Precision Medicine Mission: IDEAYA is committed to discovering, developing, and commercializing transformative cancer therapies, integrating expertise in small-molecule drug discovery, structural biology, and bioinformatics to provide first-in-class targeted therapies for molecularly defined solid tumor indications, driving the next wave of precision oncology.
See More
IDEAYA Biosciences Initiates Clinical Trial for IDE574
- Clinical Trial Launch: IDEAYA Biosciences has announced the enrollment of its first patient in the Phase 1 dose escalation trial for IDE574, aimed at evaluating the drug's safety and efficacy as a monotherapy in various solid tumor patients, showcasing the company's ongoing innovation in precision medicine.
- Target Mechanism Innovation: IDE574, a potential first-in-class oral small molecule dual inhibitor targeting KAT6 and KAT7, exhibits single-digit nanomolar cellular potency, expected to provide new treatment options for high unmet need tumor types like breast cancer, potentially transforming existing treatment paradigms.
- Antitumor Activity Validation: In preclinical models, IDE574 demonstrated superior antitumor activity compared to KAT6 inhibition alone, particularly in tumors with 8p11 amplifications and ESR1 mutations, indicating its potential to address resistance mechanisms and provide more durable treatment outcomes for patients.
- R&D Strategic Direction: IDEAYA is committed to developing transformative therapies for cancer, and the clinical advancement of IDE574 complements the company's robust pipeline focused on synthetic lethality and antibody-drug conjugates, reinforcing its leadership position in the precision oncology space.
See More
IDEAYA Biosciences Initiates Phase 1 Trial for IDE574 Dual Inhibitor
- Trial Initiation: IDEAYA Biosciences has enrolled its first patient in a Phase 1 dose escalation trial to evaluate the safety and efficacy of IDE574, a potential first-in-class oral small molecule dual inhibitor of KAT6/7, aimed at providing new treatment options for patients with various solid tumors, including breast and prostate cancer.
- Selectivity Advantage: IDE574 demonstrates single-digit to low-teen nanomolar potency in target engagement assays against KAT6 and KAT7, with a selectivity of approximately 350 to 2,000-fold over KAT5 and KAT8, which minimizes impact on normal cellular functions, enhancing its therapeutic profile.
- Significant Antitumor Activity: In preclinical models, IDE574 exhibits robust and durable monotherapy antitumor activity superior to KAT6 inhibition alone, particularly in tumors with 8p11 amplifications and ESR1 mutations, highlighting its potential to address resistance mechanisms in cancer treatment.
- Future Development Outlook: IDEAYA plans to present the potential first-in-class and best-in-class preclinical profile of IDE574 at the AACR 2026 conference, underscoring its strategic significance in addressing high unmet needs in solid tumors, particularly for breast cancer patients resistant to hormone-based therapies.
See More
IDEAYA Biosciences Initiates Phase 1 Clinical Trial for IDE849 and IDE161
- Trial Launch: IDEAYA Biosciences has announced the initiation of a Phase 1 clinical trial for IDE849 and IDE161, aimed at evaluating the efficacy of these potential first-in-class drugs in DLL3 upregulated solid tumors, marking a significant advancement in the field of precision medicine.
- Global Multi-Site Study: The clinical trial will enroll patients across North America, Europe, Australia, South America, and Asia, utilizing a 3.5 mg/kg IV dose every three weeks for dose escalation, expected to provide new treatment options for patients worldwide.
- Efficacy Observations: Among four small cell lung cancer patients pre-treated with IMDELLTRA®, three partial responses were observed, indicating the potential efficacy of IDE849 and further validating its prospects in clinical applications.
- Innovative Mechanism: The combination of IDE161, a first-in-class PARG inhibitor, with IDE849 aims to enhance anti-tumor activity by increasing the accumulation of TOP1 cleavage complexes, potentially delivering more durable efficacy for IDEAYA's ADC pipeline.
See More
IDEAYA Biosciences Advances Clinical Trials for IDE849 and IDE161
- Clinical Trial Progress: IDEAYA Biosciences has announced the initiation of its Phase 1 clinical trial for IDE849 and IDE161, aimed at evaluating the efficacy of these potential first-in-class drugs in tumors such as small cell lung cancer, showcasing the company's ongoing innovation in precision medicine.
- Dose Evaluation: Currently, IDE849 is being assessed at a dose of 3.5 mg/kg, with an expansion cohort at 2.4 mg/kg showing 3 partial responses out of 4 small cell lung cancer patients, indicating the drug's potential efficacy and tolerability in treatment.
- Global Recruitment Plan: The clinical trial will recruit patients across multiple regions including North America, Europe, Australia, South America, and Asia, reflecting IDEAYA's strategic intent to expand its clinical research globally to meet diverse medical needs.
- Combination Therapy Outlook: The combination of IDE161 as a PARG inhibitor with IDE849 is expected to enhance efficacy by increasing the accumulation of TOP1 lesions, further solidifying IDEAYA's leading position in the development of anti-tumor drugs, particularly in areas with significant unmet medical needs.
See More
IDEAYA Biosciences to Announce Phase 2/3 Trial Results
- Clinical Trial Announcement: IDEAYA Biosciences plans to issue a joint press release with Servier on April 13, 2026, at 8:00 AM ET, to disclose topline results from the ongoing Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib for HLA*A2-negative metastatic uveal melanoma patients.
- Management Participation: The conference call will feature members of IDEAYA's management alongside a distinguished key opinion leader, aiming to discuss trial results and their potential implications for the company's future, thereby enhancing investor confidence.
- Webcast Information: Investors can register for the webcast through the Events section of IDEAYA's website, and a replay will be available for 30 days post-event, ensuring that those unable to attend live can still access critical information.
- Precision Medicine Mission: IDEAYA is committed to precision oncology, focusing on the discovery, development, and commercialization of transformative therapies, integrating expertise in small-molecule drug discovery and bioinformatics to develop personalized treatment options aligned with genetic disease drivers.
See More
IDEAYA Biosciences to Announce Phase 2/3 Trial Results for Darovasertib
- Clinical Trial Announcement: IDEAYA Biosciences plans to issue a joint press release with Servier on April 13, 2026, at 8:00 AM ET, disclosing topline results from the ongoing Phase 2/3 registrational trial, OptimUM-02, which evaluates darovasertib in combination with crizotinib for first-line HLA*A2-negative metastatic uveal melanoma patients.
- Management Involvement: The conference call will feature members of IDEAYA's management alongside a distinguished key opinion leader, aiming to discuss trial results and their potential implications for the company's future, thereby enhancing investor confidence in the strategic direction.
- Webcast Information: Webcast registration details can be accessed via the Events section of IDEAYA's website, and a replay will be available for 30 days post-event, ensuring that investors who cannot attend live can still access critical information.
- Precision Medicine Mission: IDEAYA is committed to discovering, developing, and commercializing transformative cancer therapies, integrating expertise in small-molecule drug discovery, structural biology, and bioinformatics to provide first-in-class targeted therapies for molecularly defined solid tumor indications, driving the next wave of precision oncology.
See More
IDEAYA Biosciences Initiates Clinical Trial for IDE574
- Clinical Trial Launch: IDEAYA Biosciences has announced the enrollment of its first patient in the Phase 1 dose escalation trial for IDE574, aimed at evaluating the drug's safety and efficacy as a monotherapy in various solid tumor patients, showcasing the company's ongoing innovation in precision medicine.
- Target Mechanism Innovation: IDE574, a potential first-in-class oral small molecule dual inhibitor targeting KAT6 and KAT7, exhibits single-digit nanomolar cellular potency, expected to provide new treatment options for high unmet need tumor types like breast cancer, potentially transforming existing treatment paradigms.
- Antitumor Activity Validation: In preclinical models, IDE574 demonstrated superior antitumor activity compared to KAT6 inhibition alone, particularly in tumors with 8p11 amplifications and ESR1 mutations, indicating its potential to address resistance mechanisms and provide more durable treatment outcomes for patients.
- R&D Strategic Direction: IDEAYA is committed to developing transformative therapies for cancer, and the clinical advancement of IDE574 complements the company's robust pipeline focused on synthetic lethality and antibody-drug conjugates, reinforcing its leadership position in the precision oncology space.
See More
IDEAYA Biosciences Initiates Phase 1 Trial for IDE574 Dual Inhibitor
- Trial Initiation: IDEAYA Biosciences has enrolled its first patient in a Phase 1 dose escalation trial to evaluate the safety and efficacy of IDE574, a potential first-in-class oral small molecule dual inhibitor of KAT6/7, aimed at providing new treatment options for patients with various solid tumors, including breast and prostate cancer.
- Selectivity Advantage: IDE574 demonstrates single-digit to low-teen nanomolar potency in target engagement assays against KAT6 and KAT7, with a selectivity of approximately 350 to 2,000-fold over KAT5 and KAT8, which minimizes impact on normal cellular functions, enhancing its therapeutic profile.
- Significant Antitumor Activity: In preclinical models, IDE574 exhibits robust and durable monotherapy antitumor activity superior to KAT6 inhibition alone, particularly in tumors with 8p11 amplifications and ESR1 mutations, highlighting its potential to address resistance mechanisms in cancer treatment.
- Future Development Outlook: IDEAYA plans to present the potential first-in-class and best-in-class preclinical profile of IDE574 at the AACR 2026 conference, underscoring its strategic significance in addressing high unmet needs in solid tumors, particularly for breast cancer patients resistant to hormone-based therapies.
See More
IDEAYA Biosciences Initiates Phase 1 Clinical Trial for IDE849 and IDE161
- Trial Launch: IDEAYA Biosciences has announced the initiation of a Phase 1 clinical trial for IDE849 and IDE161, aimed at evaluating the efficacy of these potential first-in-class drugs in DLL3 upregulated solid tumors, marking a significant advancement in the field of precision medicine.
- Global Multi-Site Study: The clinical trial will enroll patients across North America, Europe, Australia, South America, and Asia, utilizing a 3.5 mg/kg IV dose every three weeks for dose escalation, expected to provide new treatment options for patients worldwide.
- Efficacy Observations: Among four small cell lung cancer patients pre-treated with IMDELLTRA®, three partial responses were observed, indicating the potential efficacy of IDE849 and further validating its prospects in clinical applications.
- Innovative Mechanism: The combination of IDE161, a first-in-class PARG inhibitor, with IDE849 aims to enhance anti-tumor activity by increasing the accumulation of TOP1 cleavage complexes, potentially delivering more durable efficacy for IDEAYA's ADC pipeline.
See More
IDEAYA Biosciences Advances Clinical Trials for IDE849 and IDE161
- Clinical Trial Progress: IDEAYA Biosciences has announced the initiation of its Phase 1 clinical trial for IDE849 and IDE161, aimed at evaluating the efficacy of these potential first-in-class drugs in tumors such as small cell lung cancer, showcasing the company's ongoing innovation in precision medicine.
- Dose Evaluation: Currently, IDE849 is being assessed at a dose of 3.5 mg/kg, with an expansion cohort at 2.4 mg/kg showing 3 partial responses out of 4 small cell lung cancer patients, indicating the drug's potential efficacy and tolerability in treatment.
- Global Recruitment Plan: The clinical trial will recruit patients across multiple regions including North America, Europe, Australia, South America, and Asia, reflecting IDEAYA's strategic intent to expand its clinical research globally to meet diverse medical needs.
- Combination Therapy Outlook: The combination of IDE161 as a PARG inhibitor with IDE849 is expected to enhance efficacy by increasing the accumulation of TOP1 lesions, further solidifying IDEAYA's leading position in the development of anti-tumor drugs, particularly in areas with significant unmet medical needs.
See More
